Ethicon has announced a definitive agreement to acquire NeuWave Medical. Financial terms of the transaction have not been disclosed.
NeuWave Medical’s ablation technology was originally developed by physicians and microwave scientists from the University of Wisconsin to maximise energy delivery to tissue, minimise invasiveness and provide physician-friendly workflow. NeuWave Medical’s Certus 140 ablation system’s high-powered computer and intuitive touchscreen interface is designed to enable activation of single or simultaneous multiple probe procedures for patients with soft tissue lesions. This is designed to allow physicians to effectively tailor ablations for lesions of varying shapes and sizes. NeuWave Medical’s probe family includes conventional probes and the Precision PR probe to limit ablation length, intended to allow for precise and controlled ablations.
Michael del Prado, group company chairman of Ethicon says, “…Technology and expertise that NeuWave Medical has developed is minimally invasive and can be combined with other therapies to improve outcomes for patients. Additionally, for healthcare systems, this offering can potentially translate to a lower overall financial burden.”
The closing of the transaction is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions. The transaction is expected to close during the second quarter of 2016.